All In Biotech

Drug Trial Radar · NCT07616791

A Phase I Study of INT-210 Capsules in Healthy Adult Subjects (INT-210-I101)

A Phase I, Single and Multiple Ascending Dose Escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Sep 4, 2025

Primary completion

Jan 6, 2026

Study completion Jan 6, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase Ⅰ, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Voluteers. Primary Objectives: ● To assess the safety and tolerability of single and multiple oral dose of INT-210 capsules in healthy adult voluteers, Secondary Objectives: * To assess the pharmacokinetic(PK) profile of single and multiple oral doses of INT-210 capsules in healthy adult voluteers; * To assess the safety and tolerability of INT-210 capsulese administered under fasting and fed(high-fat-meal) conditions in healthy adult voluteers; * To assess the effect of food on the PK profile of a single oral dose of INT-210 capsules in healthy adult voluteers;

Conditions

  • IBD (Inflammatory Bowel Disease)

Interventions

  • INT-210 CapsuleDrug

    400 mg INT-210; Oral administration

  • INT-210 CapsuleDrug

    Escalating doses of 50, 100, 200, 400, 600, 800 mg of INT-210; Single dose administration; Oral administration

  • INT-210 CapsuleDrug

    Escalating doses of 200, 400, 600 mg of INT-210; BID; Oral administration

  • INT-210 PlaceboDrug

    INT-210 Placebo BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of treatment-emergent adverse eventsTime frame: From Day 1 through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  2. Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematologyTime frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  3. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulationTime frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  4. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum chemistryTime frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  5. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysisTime frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  6. Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  7. Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  8. Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  9. Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  10. Treatment-emergent potentially clinically significant abnormalities in vital signs: hemoglobin saturation (%)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
  11. Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Municipality - Beijing Municipality - No. 101, Luyuan East Road, Tongzhou District, Beijing

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.